Understanding the etiology of NTS septicemia in individuals with malaria and other hemolytic disorders may lead to new strategies to reduce morbidity and mortality. To reflect the clinical association between NTS septicemia and severe malarial anemia
3-4 we have used a model in which malaria infection causes progressive hemolysis, eventually resulting in severe (but non-lethal) anemia, to assess the impact of
S. typhimurium co-infection on disease. We demonstrate that loss of resistance to
S. typhimurium requires hemolytic release of cell-free heme and subsequent induction of HO-1, and that inhibition of HO-1 reverses this susceptibility to NTS. Thus, although HO-1 is essential for tolerance to the cytotoxic effects of free heme, reducing disease severity without altering pathogen load
24-27, HO-1-mediated tolerance to malaria simultaneously impairs resistance to
S. typhimurium.
We propose () that during acute hemolysis, heme triggers immediate mobilisation of granulocytes from bone marrow to blood and generation of ROS
16, whilst simultaneously inducing HO-1 in immature myeloid cells and thereby reducing their subsequent oxidative burst capacity
30,33, perhaps by limiting the availability of heme for incorporation into NADPH oxidase
44. This results in mobilization of a heterogeneous population of granulocytes with varying levels of oxidative burst capacity. During malaria infection however, progressive hemolysis leads to sustained release of free heme which both impairs maturation of oxidative burst capacity of granulocytes in the bone marrow and mobilizes functionally immature granulocytes from bone marrow into the peripheral circulation. Accumulation in peripheral blood of functionally-impaired granulocytes, which phagocytose but are unable to kill bacteria, provides a new niche for bacterial replication and dissemination. In this scenario, HO-1 contributes to impaired resistance to NTS but heme also plays a direct role – either in granulocyte mobilization
16 or as a substrate for HO-1. The heme degradation products carbon monoxide, biliverdin and iron may further impair resistance to NTS by reducing production of ROS
21 or facilitating bacterial replication
45. In contrast, non-heme induction of HO-1 (e.g. by CoPP) may limit available iron for bacterial replication and protect phagocytic cells from apoptosis
45-46.
Our observation that hemolysis specifically suppresses the oxidative burst capacity of neutrophils offers a plausible explanation for the particular susceptibility to NTS bacteremia in individuals with hemolysis. Salmonella have evolved to survive and replicate inside mononuclear phagocytes
47; hemolysis provides an additional niche for sustained bacterial replication in circulating neutrophils. Our results are also consistent with studies of the cytoprotective role of HO-1 in mice; indeed limitation of the granulocyte oxidative burst could be an important adaptive mechanism to reduce self-damage by ROS during hemolysis and to prevent tissue injury associated with release of heme.
Very few tolerance mechanisms have been clearly identified
48, despite recent interest in their therapeutic potential
49. In mice, HO-1 confers tolerance to blood stage malaria
24-25 but simultaneously diminishes resistance to malaria parasites developing the liver
50. However, in Drosophila, infection-induced anorexia increases tolerance against
S. typhimurium but reduces resistance against
Listeria monocytogenes
51, indicating that resistance and tolerance mechanisms can be highly pathogen specific and that a mechanism of tolerance to one pathogen can diminish resistance to another. Although it is well recognized that co-infection with different pathogens can enhance disease severity, and in some cases molecular mechanisms have been elucidated
52, this study provides the first direct evidence in a mammal of tolerance to one pathogen impairing resistance to another.
To conclude, our findings have a number of important implications. First, they provide an explanation for the susceptibility to NTS bacteremia in malaria and sickle cell disease patients. Second, they imply that tolerance and resistance mechanisms identified from studies of single pathogens may not easily translate to the “real world” where people are simultaneously exposed to multiple pathogens. Specifically, the concept that the cytoprotective effects of HO-1 may be harnessed by administering its products therapeutically in humans without adversely affecting host defence against infection
53-54 may not be valid. Third, we have identified a potential adjunct therapy (SnPP) which might enhance resistance to NTS in patients with hemolytic diseases. SnPP has been used experimentally to prevent severe jaundice
55 but optimization of treatment would be crucial to avoid impairment of tolerance to heme. The experimental system described here may be a good starting point to assess and optimize such treatments.